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Abstract The binding of the ruthenium-based anticancer
drug candidates KP1019, NAMI-A and RAPTA-T
towards different double-stranded oligonucleotides was
probed by electrospray ionisation mass spectrometry and
compared with that of the widely used platinum-based
chemotherapeutics cisplatin, carboplatin and oxaliplatin. It
was found that the extent of adduct formation decreased
in the following order: cisplatin [ oxaliplatin [ NAMI-A [
RAPTA-T [ carboplatin [ KP1019. In addition to the
characterisation of the adducts formed with the DNA
models, the binding sites of the metallodrugs on the oli-
gonucleotides were elucidated employing top-down tan-
dem mass spectrometry and were found to be similar for
all the metallodrugs studied, irrespective of the sequence
of the oligonucleotide. A strong preference for guanine
residues was established.
Keywords Ruthenium  Platinum  Anticancer 
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Introduction
Following the discovery that cisplatin inhibits cell division
in bacteria by Rosenberg in the 1960s, and its subsequent
identification as a potent anticancer agent, it quickly
became, and still remains, the most widely used chemo-
therapeutic drug for the treatment of a wide range of
malignancies [1, 2]. Although cisplatin is extremely
effective against several cancers, e.g. testicular and ovarian
cancers, its application is also accompanied by severe side
effects, such as nausea, vomiting and hearing loss, and
many tumours show intrinsic or acquired resistance against
the drug. These facts led to the development and clinical
approval of platinum-based derivatives, i.e. carboplatin and
oxaliplatin (Fig. 1) [3], which mainly differ from cisplatin
in their rate of aquation and therefore their overall reac-
tivity. More recently, drugs based on metals other than
platinum, such as ruthenium, gallium, titanium and gold,
have been developed to treat cisplatin-resistant cancers [4],
and it is thought that these drugs exhibit a different mode of
action compared with platinum-based drugs and could
therefore widen the range of cancers that can be treated.
Indazolium trans-[tetrachloridobis(1H-indazole)ruthe-
nate(III)] (KP1019), imidazolium trans-[tetrachlorido(1H-
imidazole)(S-dimethyl sulfoxide)ruthenate(III)] (NAMI-A)
and [dichlorido(g6-toluene)(PTA)ruthenium(II)], where
PTA is 1,3,5-triaza-7-phosphaadamantane (RAPTA-T), all
of which incorporate ruthenium as the central atom, are
among the most promising candidates (Fig. 1) [5]. KP1019
and NAMI-A have successfully completed phase 1 clinical
trials; NAMI-A entered phase 2 clinical trials in 2008 (in
combination with a cytotoxic drug), and KP1019 is about
to follow. NAMI-A and RAPTA-T seem to be highly
effective against metastases, whereas KP1019 shows good
activity towards primary tumours. For all of the compounds
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low general toxicity combined with excellent clearance
rates was observed.
The antiproliferative activity of platinum-based anti-
cancer agents relies on interactions with DNA, binding
mainly to adjacent guanine moieties, which leads to kinks
in the molecular structure and ultimately to inducing
apoptosis [6]. Interactions with proteins, especially in the
case of ruthenium, have also been suggested to play an
important role, although direct interactions with DNA
cannot be excluded [7, 8]. Over the years, virtually all the
available bioanalytical/biophysical techniques, including
spectroscopy, chromatography, electrophoresis, X-ray dif-
fraction analysis, isotopic labeling and mass spectrometry
(MS), as well as hyphenated techniques, have been applied
to the study of metallodrug–(model) DNA interactions [9].
Following the development of electrospray ionisation
(ESI) MS and matrix-assisted laser desorption/ionisation
(MALDI) MS techniques in the late 1980s, they quickly
became invaluable for the analysis of nucleic acids and
oligonucleotides [10], and therefore also for the analysis of
metal complex–DNA interactions [11, 12]. Although
ESI-MS analysis of duplex DNA–drug interactions has
been reported on several occasions [13–15], even the most
recent studies focused primarily on the adducts formed
with single strands and the mechanisms underlying
dissociation in the gas phase [16, 17]. Cisplatin forms
mainly DNA intrastrand cross-links with nucleobases [18],
but the formation of interstrand cross-links is also possible,
and they might contribute significantly to the drug’s
activity, with enhanced repair being one of the causes of
clinical acquired resistance [19, 20]. Although ruthenium
drugs have also been shown to bind to nucleotides and
DNA [21], adduct formation proceeds more slowly com-
pared with cisplatin, therefore substantiating the hypothesis
that DNA might not be the (primary) target for this com-
pound class.
In this paper, we describe a MS-based technique for the
analysis of adducts formed between duplex DNA and
anticancer metallodrugs. Using a multistage mass-spec-
trometric top-down approach, we have elucidated the
binding sites of the metal-based drugs.
Materials and methods
ESI-MS for characterisation of duplex DNA–metallodrug
interactions was carried out with an Ultima II quadrupole
time of flight (TOF) mass spectrometer (Waters,
Manchester, UK) operated in positive and negative ion
mode. The instrument was calibrated daily using a 0.01%
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Fig. 1 Platinum-based
pharmaceuticals cisplatin (a),
carboplatin (b) and oxaliplatin
(c) and the ruthenium-based
anticancer drug candidates
KP1019 (d), NAMI-A (e) and
RAPTA-T (f). Counterions have
been omitted for clarity
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phosphoric acid solution in 50% acetonitrile. Determina-
tion of the extent of adduct formation was carried out by
monitoring the 5? and 6? charge states of the duplex and
the corresponding adducts and integrating their peak areas.
Samples containing an effective complex to duplex ratio of
3:1 were freshly prepared in 20 mM ammonium acetate
buffer at pH 7.4, and incubated in Eppendorf tubes for up
to 120 h at 37 C (duplex concentration 25 lM). Aliquots
of 20 lL were taken after 1, 3, 6, 24 and 120 h and stored
at -20 C until analysis. The samples were mixed with
100 mM ammonium acetate in methanol at a ratio of 1:1
immediately prior to analysis to enhance spray formation
and the stability of the duplex DNA in the gas phase. Data
acquisition and analysis were carried out using the Mass-
Lynx software bundle (Waters).
Fragmentation experiments for binding site elucidation
were carried out with a linear ion trap mass spectrometer
(LTQ XL, Thermo Fisher Scientific, Bremen, Germany),
specifically in negative ion mode owing to its capability to
perform multiple-stage MS/MS experiments. For identifi-
cation of unmodified fragments the Web-based Mongo
Oligo Mass calculator version 2.06 (http://library.med.utah.
edu/masspec/mongo.htm) was used [22]. Samples con-
taining an effective complex to duplex ratio of 1:1 were
prepared in ammonium acetate buffer at pH 7.4 and incu-
bated at 37 C for up to 72 h. For analysis, the samples
were diluted tenfold with a solution containing methanol/
water/n-propanol in a ratio of 65:20:5 and placed into a 96-
well plate in an Advion TriVersa nano-ESI robot (Advion
Biosciences, Ithaca, NY, USA) equipped with a 5.5-lm
nozzle chip. The ESI robot was controlled with ChipSoft
version 7.2.0 employing a gas pressure of 0.45 psi and a
spray voltage of 1.7 kV. The mass spectrometer was
operated in enhanced resolution mode and for fragmenta-
tion experiments an isolation width of 3.0 m/z and a rela-
tive collision energy of 35% were used. The Xcalibur
software bundle was utilised for data acquisition and
analysis (Thermo Fisher Scientific).
MALDI-MS experiments were carried out in linear
mode using an Axima CFR Plus (Kratos/Shimadzu Bio-
tech, Kyoto, Japan) MALDI-TOF instrument. MALDI
matrices (nicotinic acid, anthranilic acid, trihydroxyaceto-
phenone, 3-hydroxypicolinic acid and picolinic acid) were
obtained from Sigma-Aldrich (Buchs, Switzerland).
High performance liquid chromatography (HPLC)-
purified synthetic oligonucleotides were purchased from
Microsynth (Balgach, Switzerland) and DNA Technology
(Risskov, Denmark). Duplex DNA was prepared by mixing
the corresponding single strands (200 lM) in 100 mM
aqueous ammonium acetate, heating at 70C for 15 min
and then annealing by slowly cooling to 4C. Annealing
was confirmed by gel electrophoresis. Ammonium acetate
(purity more than 99.99%) and cisplatin were purchased
from Sigma-Aldrich (Switzerland), and HPLC-grade sol-
vents (water, acetonitrile, n-propanol and methanol) were
from Acros (Geel, Belgium). Oxaliplatin was purchased
from Sequoia Research Products (Pangbourne, UK).
KP1019, carboplatin, RAPTA-T and NAMI-A were syn-
thesised as described elsewhere [23–25].
Results and discussion
Optimisation of conditions
To establish the optimum technique and conditions for the
analysis of the metallodrug-modified duplex DNA, both
ESI-MS and MALDI-MS were evaluated for their suit-
ability. The first successful analysis of intact double-
stranded DNA by MALDI-MS was reported in 1995 [26]—
but owing to the considerable dissociation of the duplex
into the single strands for short oligonucleotides (less than
20-mer), the approach has mainly been used to study longer
DNA fragments [27]. Furthermore, MALDI-MS has been
used for analysis of interactions between single-stranded
oligonucleotides with ruthenium drugs [28].
For all three double strands (see Table 1 for sequences
and molecular masses), MALDI-MS experiments with
commonly used matrices containing either nicotinic acid
combined with anthranilic acid [29], 6-aza-2-thiothymine
[27, 30] and trihydroxyacetophenone [28] or a combination
of 3-hydroxypicolinic with picolinic acid [31] were carried
out. Independent of the matrix composition, the ionised
species consisted mainly of the single strands in both
positive and negative ionisation modes (see the electronic
supplementary material). Also note that analysis could only
be carried out in linear mode as the additional ion flight
time in the reflectron mode induced fragmentation of the
oligonucleotides. Consequently, no further experiments
probing the adducts formed between the duplexes and
metallodrugs were carried out as dissociation of the double
strands had to be expected for these systems as well.
Although it seems logical to perform the analysis of
oligonucleotides in negative ion mode owing to their
negatively charged phosphate backbone, good results for
intact duplex DNA–drug interaction can also be obtained
in the positive mode by ESI-MS [14, 15]. In this case,
dissociation of the double strand is probably hindered by
the presence of ammonium ions, which may stabilise the
duplex during ion transfer from solution to the gas phase
in the electrospray process. Still, the majority of publi-
cations dealing with ESI-MS of duplex DNA have
reported the utilisation of negative ion mode with high
salt concentrations in the spraying solution [13], which
has to be considered the more widely applicable instru-
ment setting.
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To establish the optimal conditions for our application,
ESI-MS spectra of the oligonucleotides and metallodrugs
were recorded in positive and negative ion mode with
various ammonium acetate concentrations between 0 and
100 mM and with methanol contents of up to 50%. Sur-
prisingly, the most satisfactory results were obtained in
positive ion mode with a spraying solution containing
50 mM ammonium acetate in 50% methanol, especially
when analysing metallodrug–olignucleotide adducts (note
that positive charges are introduced by the metallodrug
fragments). Although the signal-to-noise ratio is poorer in
positive ion mode, owing to adduct formation between the
oligonucleotides and ammonium ions as well as sodium
and potassium ions leading to additional peaks in the
spectra, increased stabilisation of the duplexes was
observed compared with the negative ion mode (see the
electronic supplementary material), especially when sam-
ples containing the oligonucleotides and metallodrugs were
analysed. Therefore, this solvent system was chosen for all
further measurements which focused on the analysis of
intact double strands. Negative ion mode was selected to
identify the preferred strand for binding of the metallo-
drugs incubated with duplex DNA in accordance with a
study reported earlier [16].
Interactions with doubled-stranded DNA
Platinum complexes
For platinum-based compounds, the main focus of attention
is on their interactions with DNA since it is considered to
be the ultimate target inside the cancer cell. A multitude of
studies on this topic has been carried out over the years,
although enzymes and proteins have also been shown to
play a role in the inhibition of transcription and conse-
quently in the induction of apoptosis [32]. The three plat-
inum compounds were incubated with the selected
oligonucleotides for up to 120 h under simulated physio-
logical conditions. Following incubation, the samples were
analysed by ESI-MS and the spectra obtained were com-
pared with those of the pure duplexes.
For samples containing the duplexes with multiple
guanines (G; it is known that binding occurs mainly
through interaction with the nucleophilic N7 of this
nucleotide), i.e. DS1 and DS2, a fast decrease of the peaks
corresponding to the unmodified oligonucleotides was
observed when incubation was carried out with cisplatin.
This was accompanied by an increase in the relative
intensity of the peaks corresponding to [DS ? Pt(NH3)2]
and [DS ? 2Pt(NH3)2] species. If the number of guanines
is reduced to one in each strand (DS3), consequently also
rendering intrastrand G–G cross-linking impossible, only
about 40% of the oligonucleotide is modified after 24 h of
incubation, whereas this number is more than doubled for
DS1 and DS2 with more than one guanine residue
(Table 2). Note that the extent of modification as shown in
Fig. 3 and Table 2 represents only an estimate as adduct
formation with the metal complexes, which introduce
additional positive charges, might lead to different ionisa-
tion characteristics compared with the unmodified oligo-
nucleotides. However, an approximation of the relative
reactivity of the different compounds can be derived from
the data.
Interestingly, even in the case of DS3 (the most prom-
inent peaks correspond to the 6? and 5? species at 1,628.3
and 1,953.8 m/z, respectively; Fig. 2), the major adduct is a
bifunctional oligo-[Pt(NH3)2] species involving coordina-
tion of the metal centre to the duplex as, for example,
evidenced by the peak at 1,999.3 m/z corresponding to
[DS3 ? Pt(NH3)2]
5? (Fig. 2). This infers that either
adenosine serves as a second binding partner to form G–A
or G–X–A (X is C, T) cross-links or interstrand cross-
linking between the two guanine residues on each strand
takes place. Indeed, both processes have been shown to be
relevant in the biological environment [33]. When spectra
are recorded in the negative mode, the majority of the
signals are attributable to single-stranded oligonucleotides,
indicating that the relative amount of interstrand cross-
links is below 5% as covalent bridging via the platinum
moiety should lead to a stable double-stranded species.
Also bisadducts detected in positive ion mode
([DS3 ? 2Pt(NH3)2]
5? at 2,044.7 m/z) indicate binding of
one metallodrug moiety to both of the strands.
Results comparable with those for cisplatin were obtained
for carboplatin and oxaliplatin, although adduct formation
proceeds more slowly compared with that for cisplatin
(Fig. 3, Table 2). This correlates to the slower aquation
kinetics of carboplatin and oxaliplatin relative to that of
cisplatin (the aquated species are believed to be essential
intermediates during the reaction) [33]. The formation of
Table 1 Sequences and masses of the complementary oligonucleotides
Sequence Monoisotopic
mass (Da)
DS1 7,904.4
SS1a 50-d(GTATTGGCACGTA)-30 3,987.7
SS1b 50-d(TACGTGCCAATAC)-30 3,916.6
DS2 7,905.4
SS2a 50-d(TACGTGCCAATAC)-30 4,003.7
SS2b 50-d(TACACACCGGTAC)-30 3,901.7
DS3 9,753.7
SS3a 50-d(ATATTATGCTTAATTA)-30 4,867.8
SS3b 50-d(TAATTAAGCATAATAT)-30 4,885.9
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adducts occurs after exchange of the dicarboxylato and ox-
alato ligands, respectively, resulting in mainly bifunctional
cross-links, as evidenced, for example, by the peak
at 2,015.3 m/z corresponding to [DS3 ? Pt(DACH)]5?
(DACH is 1,2-diaminocyclohexane) for oxaliplatin in
Fig. 2. Also, the formation of a bisadduct similar to the case
of cisplatin can be observed ([DS3 ? 2Pt(DACH)]5? at
2,076.6 m/z); for carboplatin, the spectrum resembles that of
cisplatin (although with lower intensities for the metallodrug
adducts relative to the free unmodified oligonucleotides),
with a major peak at 1,999.3 m/z corresponding to
[DS3 ? Pt(NH3)2]
5? (not shown). For reactions with DS3,
no significant formation of interstrand cross-links was
observed, as evidenced by spectra recorded in negative ion
mode. A list of metallodrug species bound to the oligonu-
cleotides is given in Table 2.
Even though dissociation of the double strands in the
negative ion mode seems disadvantageous, it provides
information on the distribution of the metal complexes
between the single strands. For DS1 a slight preference for
binding towards SS1a was observed, for DS2 a preference
for SS2a and for DS3 adduct formation with both strands
proceeds at approximately the same rate. These preferences
can be explained by the higher number of guanine residues
in the respective strands, and additionally, for example, by
the presence of the advantageous sequence TGGC in SS1a
compared with GTG in SS1b [34].
Ruthenium complexes
The reactivity of ruthenium compounds towards nucleo-
tides has already been demonstrated [35], although a
different mode of action as compared with the platinum
drugs including protein interactions has been proposed by
several authors [36]. Such interactions might explain their
activity towards cisplatin-resistant cancer cells as well as
the antimetastatic properties of NAMI-A and RAPTA-T
[37, 38].
Analogous to the experiments with the platinum com-
pounds, all measurements were carried out in both positive
and negative ion mode. When the spectra of the unmodified
oligonucleotides are compared with those of the ruthenated
oligonucleotides, it can be deduced from the differences in
mass that the compounds have to undergo ligand exchange
before or on binding to the oligonucleotides. For RAPTA-T,
the major adducts were assigned to [Ru(PTA)]- and
[Ru(PTA)(T)]-containing species. For NAMI-A, the most
prominent adduct peaks correspond to the oligonucleotides
with the [Ru(Im)] moiety (Im is imidazole) is attached,
whereas [Ru(Ind)] and [Ru(Ind)2] adducts (Ind is indazole)
are found for samples incubated with KP1019. As a series
of aquated species are detected for NAMI-A and KP1019,
which results in a higher number of possible adducts, data
analysis is complicated compared with that for the samples
with platinum compounds. The apparently multidentate
nature of the binding to DNA severely changes its sec-
ondary structure, leading to dissociation of the duplex into
its single strands upon binding of the ruthenium-based
drugs. Consequently, almost no adduct formation between
intact duplex DNA and the drugs could be detected and
negative ion mode provided information similar to that for
positive ion mode, although at higher signal-to-noise ratios
(see the electronic supplementary material). Additionally,
the nature of the adducts was confirmed by measurements
Table 2 Assignment of adducts
formed between
oligonucleotides and the
metallodrugs studied as well as
the estimated percentage of
oligonucleotide modified after
an incubation period of 24 h
DACH 1,2-
diaminocyclohexane, PTA
1,3,5-triaza-7-
phosphaadamantane, Ind
indazole, Im imidazole
Drug Adducts Average
mass (Da)
Relative amount of modified duplex after 24 h (%)
DS1 DS2 DS3
Cisplatin Pt(NH3)2 229.1 89 84 40
Pt(NH3)2Cl 264.6
Carboplatin Pt(NH3)2 229.1 29 24 24
Oxaliplatin Pt(DACH) 309.3 68 51 34
RAPTA-T Ru(PTA) 258.2 46 37 36
Ru(PTA)(T) 350.4
Ru(PTA)(T)Cl 385.8
KP1019 Ru 101.9 13 18 15
Ru(Ind) 219.2
Ru(Ind)(H2O) 237.2
Ru(Ind)(H2O)2 255.2
Ru(Ind)2 337.3
NAMI-A Ru 101.9 60 53 27
Ru(Im) 169.1
Ru(Im)(H2O) 187.1
Ru(Im)(H2O)2 205.1
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in negative ion mode as loss of the chlorido ligands could
otherwise be interpreted as an artefact during ionisation in
positive ion mode. Furthermore, data on the preferred
strand were obtained owing to the dissociation of the
double strand, showing a higher extent of adduct formation
for single strands SS1a and SS2a similar to the platinum
compounds. Again, no difference was observed for SS3a
and SS3b. It was expected that RAPTA-T would form the
greatest number of adducts since the ruthenium centre in
this compound is in the more reactive ?II oxidation state
compared with ?III in KP1019 and NAMI-A [7]. Sur-
prisingly, the double strands are modified to the greatest
extent by NAMI-A, whereas KP1019 only shows very little
interaction with the oligonucleotides (Fig. 3, Table 2).
These observations might be explained by the hydrolysis
kinetics of the compounds; according to previous studies
[39, 40], NAMI-A is aquated more rapidly than RAPTA
compounds.
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Fig. 3 Estimated extent of binding of the metallodrugs studied
towards duplex DNA. Top DS1, middle DS2 and bottom DS3
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Fig. 2 Electrospray ionisation time of flight (ESI TOF) mass spectra
showing the interactions between DS3 and platinum-based chemo-
therapeutics. Top unmodified DS3, middle DS3 ? cisplatin (incuba-
tion with carboplatin yields the same adducts albeit with lower
relative intensity) and bottom DS3 ? oxaliplatin. DACH 1,2-
diaminocyclohexane
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As depicted in Fig. 4 for DS2, the most intense ions are
found for the -5 charge state, with the monoisotopic peaks
at 799.8 and 779.4 m/z assigned to unmodified SS2a and
SS2b, respectively, when the instrument was operated in
negative ion mode. Minor peaks stemming from adduct
formation with sodium, potassium and ammonium ions are
also present in the spectra but have not been labelled for
clarity. For RAPTA-T, the two chlorido ligands are lost on
binding, but during prolonged incubation also the aromatic
toluene ring is displaced, as noted previously for other
RAPTA compounds [41, 42], resulting in peaks at m/z
values of 832.4 and 850.9 for [SS2b ? Ru(PTA)]5- and
[SS2b ? Ru(PTA)(T)]5- (Fig. 4, top spectrum). Similarly,
peaks with slightly higher relative intensities at 852.9 and
871.3 m/z were assigned to [SS2a ? Ru(PTA)]5- and
[SS2a ? Ru(PTA)(T)]5-, respectively. Adducts containing
the [Ru(PTA)(T)Cl]- moiety are only present at very low
intensities for incubation times longer than 6 h.
NAMI-A undergoes a more complicated series of
hydrolysis reactions prior to the formation of stable adducts
with biomolecules. Indeed, in a previous study character-
ising the interactions of NAMI-A with cytochrome c, it was
shown that the chlorido ligands have to be substituted
(partially by aqua ligands) to form a stable adduct
[43]. Consequently, the peaks in Fig. 4 (bottom spectrum)
at 814.6, 818.2 and 821.8 m/z have been assigned
to [SS2b ? Ru(Im)]5-, [SS2b ? Ru(Im)(H2O)]
5- and
[SS2b ? Ru(Im)(H2O)2]
5-, respectively, whereas the
peaks at 832.6, 836.2 and 839.8 m/z correspond to similar
adducts formed with SS2a. Furthermore, the peaks at
868.8, 872.4, 876.0 and 879.6 m/z indicate binding of even
two partially aquated Ru(Im) containing moieties to SS2a,
which in general seemed to be the preferred binding partner
owing to the higher number of guanosine residues.
Although the rate of aquation of the chlorido ligands of
KP1019 is comparable to that of NAMI-A, there is a sec-
ond nitrogen-containing heterocycle coordinated to ruthe-
nium which is more strongly coordinating than the
dimethyl sulfoxide ligand in NAMI-A. As these nitrogen
donor ligands are in a trans position to each other, binding
to the oligonucleotide could be sterically hindered, there-
fore explaining the lower extent of adduct formation. The
major peaks in Fig. 4 for the KP1019–DS2 interaction
(middle spectrum) where assigned as follows: 824.5 m/z to
[SS2b ? Ru(Ind)]5-, 848.6 m/z to [SS2b ? Ru(Ind)2]
5-,
845.0 m/z to [SS2a ? Ru(Ind)]5- and 868.5 m/z to
[SS2a ? Ru(Ind)2]
5-. Also note that there is a series of
minor peaks corresponding to the aquated species of the
Ru(Ind) moiety.
For both KP1019 and NAMI-A, even adducts with only
the ruthenium centre (loss of all original ligands) coordi-
nated to the oligonucleotides were detected after incubation
times of 5 days, whereas the PTA ligand stays coordinated
to ruthenium in RAPTA-T. This result is rather surprising
as loss of the nitrogen-containing ligands in KP1019 and
NAMI-A was not observed in earlier protein binding
experiments; in our study, the ligand exchange could be
induced sterically owing to the flexibility of the oligonu-
cleotide. A list of metallodrug species found bound to the
oligonucleotides is given in Table 2.
Binding site determination
To establish the binding site of the metallodrugs, i.e. the
metalated nucleobases, MS/MS experiments using colli-
sion-induced dissociation (CID) were carried out. CID of
double-stranded DNA yields mainly the intact single
Fig. 4 Negative ion mode ESI TOF mass spectra showing the
interactions between DS2 and ruthenium-based compounds after an
incubation period of 6 h. Dissociation into the single strands SS2a
(open diamonds) and SS2b (filled diamonds) (charge states -6 to -4)
takes place under the selected conditions and the different extent of
adduct formation depending on the strand and the compound is
demonstrated (top RAPTA-T, middle KP1019 and bottom NAMI-A).
Only the most intense adduct peaks for each compound are labelled
for the -5 charge state. PTA 1,3,5-triaza-7-phosphaadamantane, Ind
indazole, Im imidazole
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strands, and their further fragmentation in positive ion
mode results only in large oligonucleotide fragments (the
phosphate groups on the nucleotides induce low ionisation
efficiency for short sequences in positive ion mode) that
give little structural information. Therefore, fragmentation
experiments were carried out in negative ion mode with an
ion trap instrument capable of MSn analysis. Owing to the
characteristic isotopic pattern, induced by coordination of
the metals to the oligonucleotides, metal-free species could
easily be distinguished from the modified oligonucleotides.
The commonly applied nomenclature for oligonucleo-
tide fragments is summarised in Fig. 5 [44]. For n-type
fragments, Bn (B is one of the nucleobases A, C, G or T) is
usually lost by an elimination reaction prior to strand
breaking, which is caused by a second elimination reaction,
leading to a furan ring system [44]. Internal fragments,
resulting from two strand breaks at the a/w site, possess a
phosphate group at their 50 terminus, whereas the 30 ter-
minus carries a furan system.
Platinum complexes
The interaction of cisplatin with DS1 and DS2 was char-
acterised by ESI-MS/MS earlier, revealing GG and GTG as
the major binding sites [16]. In this study, we wanted to
verify that the preference towards guanine residues is
maintained even if adenine and thymine are present in
large excess as in DS3, and, additionally, establish the
preferred binding sites for the platinum-based pharmaceu-
ticals oxaliplatin and carboplatin. Previous studies have
shown that both oxaliplatin and carboplatin form adducts
with DNA comparable to those of cisplatin, showing also a
strong preference for guanosine as the major binding
partner [46, 47].
For this purpose, the ions of the Pt(NH3)2 (for cisplatin
and carboplatin) and Pt(DACH) (for oxaliplatin) adducts of
the single-stranded oligonucleotides were isolated and
subjected to CID. As expected, binding towards the oli-
gonucleotides takes place mainly at guanine-containing
residues, even in the case of DS3. The formation of com-
plementary modified and unmodified (an–Bn), wn and
internal (Bn:Bm) fragments comparable to those found in
peptide fragmentation experiments in proteomics gives the
exact metal binding site. As the coordination of the metal
might result in fragmentation mechanisms additional to
standard single fragmentation pathways, i.e. a, b, c, d and
w, x, y, z fragments as well as internal a/w-type fragments,
not all the peaks could be assigned.
In Fig. 6, an expanded segment of a representative CID
spectrum for the binding site determination on DS2 incu-
bated with a metallodrug (in this case oxaliplatin) is depic-
ted. In this case, the peak corresponding to [SS2b ?
Pt(DACH)]3- at 1,402.2 m/z was isolated in the ion trap of
the instrument and subjected to fragmentation. The major
peaks in the resulting CID spectrum correspond to [SS2b-
C ? Pt(DACH)]3- at 1,365.0 m/z, as well as the non-plat-
inum-containing fragments [a4–A]
- and [a5–C]
- at 1,003.1
and 1,316.0 m/z, respectively. It can be seen that all (an–Bn)-
type fragments from the 50 terminus up to the guanine resi-
due at position 9 remain unmodified (as evidenced, e.g., by
the non-platinum peak at 1,247.6 m/z, which was assigned to
[a9–G]
2-), whereas all (an–Bn) fragments from there on
exhibit an isotopic pattern characteristic for platinum. This
can be attributed to the attachment of the Pt(DACH) moiety,
which leads to a mass increase of 307.1 Da (neutral species).
Consequently, the peak at 1,566.0 m/z can be identified as
[a10–G ? Pt(DACH)]
2-. Complementarily, all wn-type
fragments from the 30 terminus up to w4 (1,252.1 m/z)
remain unmodified, whereas all further wn fragments (which
include the G9 residue) are modified by Pt(DACH). This is
evidenced by, for example, the singly charged peak at
1,888.1 m/z, with an isotopic pattern characteristic for
platinum and which can be assigned to [w5 ? Pt(DACH)]
-.
By combining the information gained from the modified and
unmodified fragments from both the 30 and 50 terminus, we
can unambiguously identify the G9 residue as the nucleotide
mainly involved in the platinum binding. Note that not
all detected fragment ions are contained in the expanded
Fig. 5 Nomenclature of oligonucleotide fragments observed by MS/MS. a–d fragments correspond to fragments with an intact 50 terminus and
w–z-type fragments have an intact 30 terminus. Internal fragments resulting from double fragmentation usually occur at the a/w site
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segments of the spectrum (Fig. 6). Calculated and experi-
mental m/z values for the peaks in Fig. 6 are listed in
Table 3.
Fragmentation experiments with the other oligonucleo-
tides and platinum complexes were carried out in a similar
fashion and revealed guanine as the major binding partner
for the other platinum complexes and all other single
strands. For SS1a, the neighbouring G–G residues at
positions 6 and 7 were identified. For SS1b, G6 appears to
be preferred over G4. For SS2a, which contains five
guanine residues, again adjacent G–G residues at positions
6 and 7 show stronger interaction than G–T–G sequences.
For SS3a and SS3b, despite the fact that there is only one
guanine residue present, no binding to adenine and thymine
residues was detected. In all cases, mainly (an–Bn), wn and
internal (Bn:Bm) fragments were observed.
Ruthenium complexes
NMR and gel electrophoresis studies suggest that NAMI-
A, RAPTA and KP1019 exhibit similar reactivity towards
adenine and guanine in plasmid DNA [35, 48], and capil-
lary electrophoresis inductively coupled plasma MS studies
have shown that RAPTA compounds and KP1019 can react
with the DNA model compound 50-dGMP [39]. In NMR
studies with different ruthenium–arene complexes with
single nucleotides, thymine residues were also suggested as
binding partners in addition to guanosine. However, under
these conditions, steric effects resulting from the three-
dimensional structure of oligonucleotides, which makes the
N3 of thymine virtually inaccessible, are not taken into
account, which is the major disadvantage of single nucle-
otide DNA models [49]. Subsequent two-dimensional
NMR studies employing 14-mer oligonucleotides con-
firmed adduct formation with guanines and suggested
intercalation and stacking interactions of the arene ligand
with adjacent thymine residues [21]. Although DNA might
not be the main target of ruthenium compounds in terms of
their anticancer activity, reactions with single nucleotides,
oligonucleotides and RNA molecules present in the cyto-
plasm, cannot be ruled out.
As an example, expanded segments of a CID spectrum
corresponding to a [SS3a ? Ru(PTA)]4- parent ion (con-
taining only one guanine residue) fragmentation are
depicted in Fig. 7. Assignment of the fragment ions was
conducted in a fashion similar to that for the platinum
compounds, and the majority of CID product ions could be
assigned to wn- and (an–Bn)-type strand breaks as well as
internal (Bn:Bm) fragments. Again, some product ions
could not be assigned, most probably owing to a different
fragmentation mechanism induced by the bound metal.
After assigning the peaks to their corresponding frag-
mentation pathways and confirming characteristic isotopic
Table 3 Calculated and experimental m/z values for fragment ions
found in Fig. 6 (monoisotopic peaks)
Ion Calculated m/z Experimental m/z
[a4–A]
- 1,003.2 1,003.1
[a5–C]
- 1,316.2 1,316.1
[a6–A]
- 1,605.3 1,605.0
[a9–G]
2- 1,247.7 1,247.6
[a10 ? Pt(DACH)]
2- 1,565.8 1,566.0
[a12 ? Pt(DACH)]
2- 1,882.3 1,882.1
w4
- 1,252.2 1,252.1
[w5 ? Pt(DACH)]
- 1,888.4 1,888.1
[w6 ? Pt(DACH)]
2- 1,088.2 1,088.5
[w7 ? Pt(DACH)]
2- 1,232.7 1,232.6
[w9 ? Pt(DACH)]
2- 1,533.8 1,533.6
[w10 ? Pt(DACH)]
2- 1,690.3 1,690.0
[w11 ? Pt(DACH)]
2- 1,834.8 1,835.0
[SS2b-C ? Pt(DACH)]3- 1,365.3 1,365.1
Fig. 6 An expanded segment of
an LTQ collision induced
dissociation (CID) mass
spectrum of SS2b modified by
oxaliplatin in the range from
950 to 1,900 m/z that contains
the majority of platinum-
containing fragments.
Unidentified fragments
exhibiting an isotopic
distribution characteristic for
platinum are labelled X
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patterns for modified residues, we identified the major
binding partner. Again starting from the 50 terminus, it
becomes clear that up to [a8–G]
2- (1,125.6 m/z) mainly
unmodified residues are detected, whereas from there on all
(an–Bn) fragments, which incorporate the guanine residue,
contain the Ru(PTA) moiety (mass increase of 256.0 Da
for the neutral species), for example, evidenced by
[a9–C ? Ru(PTA)]
2- at 1,418.5 m/z. Complementary infor-
mation was obtained by assigning the fragments starting
from the 30 terminus: up to w7, the peaks can be assigned to
unmodified fragments, whereas w7
2- was detected in both
the unmodified (1,085.6 m/z) and [w7 ? Ru(PTA)]
2-
(1,213.6 m/z) forms. All further wn fragments with n [ 7
were found with the Ru(PTA) moiety attached. This sug-
gests that the T10 residue might serve as an additional
binding partner for the ruthenium drug to form a mulitd-
entate adduct. Additionally, modified internal fragments
such as [T7:T11 ? Ru(PTA)]2- (969.5 m/z), [A3:T11 ?
Ru(PTA)]2- (1,598.5 m/z) and [T4:G8 ? Ru(PTA)]-
(1,987.0 m/z), all of which contain the G8 residue, were
detected. Although small peaks attributable to, for exam-
ple, [w4 ? Ru(PTA)]
- (1,508.0 m/z) and [a6–A ?
Ru(PTA)]- (1,891.9 m/z) indicate that adduct formation is
also possible with adenine or thymine residues (as they do
not contain G8), the majority of the modified fragment ions
point to G8 as the preferred binding partner. Interestingly,
no loss of the PTA ligand was observed during CID. Some
of the peaks correspond to more than one species, as, for
example, internal [T2:T5] and [T4:T7] fragments exhibit
the same mass (peaks at 700.6 and 1,402.0 m/z for singly
and doubly charged species, respectively). In Table 4, the
calculated and observed m/z values for the modified frag-
ment ions from Fig. 7 are listed.
For RAPTA-T, adducts of Ru(PTA) with the other sin-
gle strands were further analysed, and Ru(Im) and Ru(Ind)
adducts were subjected to CID for NAMI-A and KP1019,
respectively. Surprisingly, even for DS3, which contains
mainly adenine and thymine residues, a behaviour com-
parable to that of the platinum-based chemotherapeutics
(i.e. preference for guanine) was observed. Similar obser-
vations were made for KP1019 and NAMI-A.
Also for the other strands, the results did not differ
strongly from those obtained with the platinum-based
complexes: in SS1a, G6 and G7 are preferred binding
partners, G6 is the preferred binding partner in SS1b, G6
and G7 are preferred binding partners in SS2a and G9 is the
Fig. 7 Expanded segments of
an LTQ CID mass spectrum of
[SS3a ? Ru(PTA)]4-. Top m/z
range from 650 to 1,275 and
bottom m/z range from 1,275 to
2,000. Unidentified fragments
displaying an isotopic pattern
characteristic for ruthenium are
labelled X. Note that not all
detected fragment ions are
contained in the expanded
segments
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preferred binding partner in SS2b. In addition, low-inten-
sity peaks attributable to interactions with other residues
were detected.
Discussion
In this paper, we have presented a comparative study of the
adduct formation between duplex DNA and platinum- and
ruthenium-based anticancer drugs by MS. Note that this is
the first example of a top-down MS/MS approach for the
elucidation of binding sites on DNA fragments using CID
of selected adducts for ruthenium-based pharmaceuticals,
as well as for oxaliplatin and carboplatin. Interestingly, MS
performed in the positive ion mode was more informative
for the characterisation of the double strand–metallodrug
adducts than negative ion mode MS. Positively charged
adducts appear to be more stable in the gas phase under the
experimental conditions employed for this application.
Time course experiments confirmed cisplatin, with its
monodentate chlorido ligands, to be the most efficient
compound in terms of adduct formation over the other
platinum complexes, with their bidentate biscarboxylates,
whereas NAMI-A was more reactive towards the double-
stranded oligonucleotides than RAPTA-T and KP1019 for
ruthenium-based compounds. However, to confirm the
applicability of the proposed method for accurate quanti-
tative kinetics, validation with a complementary analytical
technique such as spectroscopy, chromatography or (cap-
illary) electrophoresis would have to be carried out.
The top-down approach used to determine the binding
partner on the oligonucleotides has several advantages in
comparison with enzymatic digestion: primarily, exonuc-
leases normally used for the removal of terminal nucleotides
do not recognise nucleotides modified by metallodrugs,
therefore inhibiting the digestion reaction and yielding an
incomplete data set. The combination of enzymes simulta-
neously attacking from the 30 and 50 ends partially circum-
vents this problem, but in the case of multiple binding, again
only incomplete data are obtained. Moreover, the top-down
approach is much more rapid than the enzymatic digestion
procedure, which might also require change of pH and
addition of catalytically active cations, which could interfere
with the interaction of the metallodrug with the oligonu-
cleotide. Several factors have to be considered in the mul-
tistage mass-spectrometric approach: the adducts formed
must be sufficiently stable to not be cleaved during CID
experiments, therefore requiring covalent bonding to the
oligonucleotide; furthermore, positive charges are intro-
duced by the metals, making it difficult to characterise short
modified oligonucleotides (consisting of less than three
bases) in negative ion mode, usually employed for this kind
of experiment. Nevertheless, as CID yields complementary
fragments, i.e. ions from the 30 and 50 ends of the biomole-
cule, complete sequence coverage can be achieved and
internal fragments can substantiate assumptions of specific
binding partners. The results described herein show that
guanine is the preferred binding partner for both platinum-
and ruthenium-based metallodrugs, even if other bases are
present in large excess, although minor peaks indicate that
adenine or thymine could also serve as a binding partner for
the ruthenium compounds. This is in good agreement with
data obtained by other techniques, including two-dimen-
sional NMR and biochemical assays, which also showed that
adduct formation between DNA and both platinum and
ruthenium compounds occurs mainly via adduct formation
with guanosine [21].
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